These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27312037)

  • 41. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis.
    Gagnière J; Veziant J; Pereira B; Pezet D; Le Roy B; Slim K
    Ann Surg Oncol; 2018 Mar; 25(3):709-719. PubMed ID: 29282602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Doud AN; Randle RW; Clark CJ; Levine EA; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2015 May; 22(5):1645-50. PubMed ID: 25120249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
    Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
    J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
    Baratti D; Kusamura S; Iusco D; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
    Dis Colon Rectum; 2014 Jul; 57(7):858-68. PubMed ID: 24901687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
    Schneider MA; Eshmuminov D; Lehmann K
    Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of EPIC Versus HIPEC in the Treatment of Colorectal Peritoneal Metastases and Appendix Tumors Using Inverse Probability of Treatment Weighting.
    Jeong MH; Kang SJ; Park SY; Kwak SG; Seo AN; Park S; Park JS; Kim HJ; Choi GS
    Ann Surg Oncol; 2024 Oct; 31(10):7111-7121. PubMed ID: 39073661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study.
    Kotha NV; Baumgartner JM; Veerapong J; Cloyd JM; Ahmed A; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Dessureault S; Clarke C; Mogal H; Zaidi MY; Russell MC; Patel SH; Sussman JJ; Dhar V; Lambert LA; Hendrix RJ; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Greer JB; Fackche N; Lowy AM; Kelly KJ
    Ann Surg Oncol; 2019 Jul; 26(7):2234-2240. PubMed ID: 31016486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.
    Goéré D; Souadka A; Faron M; Cloutier AS; Viana B; Honoré C; Dumont F; Elias D
    Ann Surg Oncol; 2015 Sep; 22(9):2958-64. PubMed ID: 25631064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries.
    Mogal HD; Levine EA; Russell G; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2016 Feb; 23(2):534-8. PubMed ID: 26289808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center.
    Liu Y; Ishibashi H; Takeshita K; Mizumoto A; Hirano M; Sako S; Takegawa S; Takao N; Ichinose M; Yonemura Y
    Ann Surg Oncol; 2016 May; 23(5):1625-31. PubMed ID: 26717938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for patients at High-Risk of Peritoneal Metastases.
    Morris MC; Dhar VK; Stevenson MA; Winer LK; Lee TC; Wang J; Ahmad SA; Patel SH; Sussman JJ; Abbott DE
    Surg Oncol; 2019 Dec; 31():33-37. PubMed ID: 31518971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
    Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
    J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.